Share
TRUEinvivo® is pleased to announce that the patent for the DOSEmapper™ TLD bead strings and Automated DOSEmapper™ TLD Reader was granted in the EU on 6th January 2021. The patent number is EP3341754. This reinforces the first patent grant which was in the USA back in January 2020. The company has further patents pending in key large countries which have high numbers of radiotherapy cancer treatment centres.
on PATENTSCOP
on Espacenet
Related Posts
TRUEinvivo's 2018 achievements include prototype development, patent filings, fundraising, multiple awards, and market expansion, setting the stage for a busy 2019.
Mount Vernon Cancer Centre pioneers first internal invivo dosimetry with TRUEnvivo® DOSEmapper™, revolutionising radiotherapy precision, patient safety, and treatment accuracy.
TRUEinvivo showcases micro silica beads at ICDA-2, University of Surrey, fostering international connections and collaborations.
TRUEinvivo wins Business Innovation of the Year Award for DOSEmapper™ technology, revolutionizing radiotherapy safety.
